Table 1. Summary of prospectively predicted TCRs from four patient tumor TILs to identify antitumor, neoantigen-reactive TCRs using the NeoTCR gene signature.
Prospective prediction of TCRs reactive with tumor | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CD8 | CD4 | All | |||||||||||
Tumor | Tested | Tumor and NeoAg-reactive |
NeoAg only | Tumor only | Total | Tested | NeoAg-reactive | TAA-reactive | Tumor only | Total | Tested | Total | % |
4393 | 8 | 4 | 0 | 3 | 7 | 6 | 3 | 1 | 0 | 4 | 14 | 11 | 79 |
4394 | 12 | 2 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 12 | 3 | 25 |
4400 | 15 | 0 | 0 | 9 | 9 | 14 | 5 | 0 | 0 | 5 | 29 | 14 | 48 |
4421 | 7 | 3 | 2 | 2 | 7 | 11 | 2 | 0 | 0 | 2 | 18 | 9 | 50 |
All | 42 | 9 | 2 | 15 | 26 61.9% |
31 | 10 | 1 | 0 | 11 35.4% |
73 | 37 | 50.7 |